Evidence map›Paper›PMID 26646052›Full record

Observational studyBMJ (Clinical research ed.)2015

HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study.

Rozalina G McCoy, Holly K Van Houten, Joseph S Ross, Victor M Montori, Nilay D Shah

Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in BMJ (Clinical research ed.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 60 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Timings for HbADiabetic medicine : a journal of the British Diabetic Association · 2019
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Rozalina G McCoyDivision of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic mccoy.rozalina@mayo.edu.
Holly K Van HoutenDivision of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic Robert D and Patricia E Kern Center for Science of Health Care Delivery, Mayo Clinic.
Joseph S RossSection of General Internal Medicine and Robert Wood Johnson Clinical Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven.
Victor M MontoriDivision of Endocrinology Metabolism and Nutrition, Department of Medicine, Mayo Clinic Knowledge and Evaluation Research Unit, Mayo Clinic.
Nilay D ShahDivision of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic Optum Labs, Cambridge, MA, USA.
Mayo Clinic in Arizona · USMayo Clinic in Florida · USRobert Wood Johnson Foundation · US

Funding

Translating Information on Comparative Effectiveness into PracticeR18HS018339 · AHRQ · MAYO CLINIC ROCHESTER · PI SHAH, NILAY D · 2009 to 2013
$1.9M
AHRQ HHS R18HS18339
6 · The paper itself

Abstract

study questionWhat is the extent and effect of excessive testing for glycated hemoglobin (HbA1c) among adults with controlled type 2 diabetes?

methodsA retrospective analysis of data from a national administrative claims database included commercially insured individuals in the USA, 2001-13. Study patients were aged 18 years or older, had type 2 diabetes with stable glycemic control (two consecutive tests showing HbA1c<7.0% within 24 months), did not use insulin, had no history of severe hypoglycemia or hyperglycemia, and were not pregnant. HbA1c testing frequency was measured within 24 months after the second (index) HbA1c test, and classified as guideline recommended (≤ 2 times/year), frequent (3-4 times/year), and excessive (≥ 5 times/year). Changes in treatment regimen were ascertained within three months of the index test. STUDY ANSWER AND LIMITATIONS: Of 31,545 patients in the study cohort (mean age 58 years; mean index HbA1c 6.2%), HbA1c testing frequency was excessive in 6% and frequent in 55%. Despite good glycemic control at baseline, treatment was further intensified by addition of glucose lowering drugs or insulin in 8.4% of patients (comprising 13%, 9%, and 7% of those tested excessively, frequently, and per guidelines, respectively; P<0.001). Compared with guideline recommended testing, excessive testing was associated with treatment intensification (odds ratio 1.35 (95% confidence interval 1.22 to 1.50)). Excessive testing rates remained unchanged in 2001-08, but fell significantly after 2009. The odds of excessive testing was 46% lower in 2011 than in 2001-02. The study population is not representative of all US patients with type 2 diabetes because it was restricted to commercially insured adults with stable and controlled diabetes not receiving insulin treatment. The study design did not capture the underuse of HbA1c testing. WHAT THIS STUDY ADDS: In this US cohort of adults with stable and controlled type 2 diabetes, more than 60% received too many HbA1c tests, a practice associated with potential overtreatment with hypoglycemic drugs. Excessive testing contributes to the growing problem of waste in healthcare and increased patient burden in diabetes management. FUNDING, COMPETING INTERESTS, DATA SHARING: NDS and RGM are funded partly by the Agency for Healthcare Research and Quality (R18HS18339) and AcademyHealth Delivery System Science Fellowship (2013), respectively. No competing interests declared. Additional data are available from mccoy.rozalina@mayo.edu.

Indexed as

AdolescentAdultAgedBlood GlucoseDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMedical OveruseMiddle AgedPrevalenceRetrospective StudiesUnited StatesYoung AdultBlood GlucoseGlycated HemoglobinHypoglycemic Agents

Identifiers

PMID26646052
PMCPMC4673101
OpenAlexW2194259989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.